Pfizer Investor Presentation — April 2019

Document content

Earnings Teleconference

April 30, 2019 Introduction

Senior Vice President,

First Quarter 2019 Earnings First Quarter 2019 Earnings

3 Forward -Looking Statements and

Non-GAAP Financial Information

 Our discussions during this conference call will include forward- looking statements about, among other things, our anticipated future

operating and financial performance, business plans and prospects, expectations for in- line products and product candidates,

including anticipated regulatory submissions, data read- outs, study starts, approvals, revenue contribution, growth performance,

timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, business- development plans, the benefits

anticipated from the reorganization of our commercial operations into three businesses which became effective at the beginning of

our 2019 fiscal year, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities and prospects, manufacturing and product supply and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied

by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10- K for the f iscal

year ended December 31, 2018 and in our subsequent reports on Form 10- Q, including in the sections thereof captioned “Risk

Factors” and “Forward- Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on

Form 8 -K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov